Guggenheim Downgrades Sionna Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 84.1%

Neg 84.1% Neu 0% Pos 0%

Guggenheim analyst Yatin Suneja downgrades Sionna Therapeutics (NASDAQ:SION) from Buy to Neutral.

Comments

No comments yet. Be the first!